Turkey: Data Exclusivity For Pharmaceutical Drugs In Turkey

In Turkey, a process called an "abbreviated application" allows generic drug producers to apply for marketing authorization without submitting information about tests and clinical trials, if a data exclusivity period does not exist, in certain circumstances. Data exclusivity enables drug producers to keep their test and clinical trial data confidential, for up to six years. The exclusivity period starts from the date that a pharmaceutical product first receives marketing authorization in a country which is a member of the European Union–Turkey Customs Union (sub-paragraph of Article 9 of the Regulation on Licensing of Human Medicinal Products dated January 19, 2005 numbered 25705 ("Regulation")). During the exclusivity period, generic drug producers cannot refer to the information gathered by the original marketing authorization holder.

A. The Concept Of Data Exclusivity – Legal Protection For Commercial Investment

The primary intellectual property rights relevant to pharmaceutical companies are trademark, patent, trade secrets and data exclusivity. Since R&D activities in this industry are greatly complicated, patent protection alone is inadequate to effectively protect and safeguard the resulting intellectual property. Therefore, one of the most important rights in this area is data exclusivity, which has a direct effect on the ability to market a pharmaceutical product.

In Turkey, no pharmaceutical product for human use may be marketed unless it is authorized by the Ministry of Health ("MoH"). In granting a marketing authorization, the MoH requires drug producers to submit the results of their pharmaceutical products' safety and efficacy tests, along with other documents regarding the product. In effect, drug producers must invent and develop a pharmaceutical drug product through intensive and time consuming studies, then provide the results of the toxicological and pharmacological tests and clinical trials to the MoH in order to obtain a marketing authorization to commercially exploit their product. Here data exclusivity provides original drug producers with protection for the information gathered from their clinical trials and studies. During the data exclusivity period, generic drug producers cannot use or rely on that data in order to obtain marketing authorization from the MoH for the same drug.

Parties in favor of data exclusivity argue that generating the data required to obtain marketing approval for an original drug requires a significant investment of time, expertise, resources and money. It would arguably be unfair and unjust to allowing generic companies to produce generic versions of patented drugs without incurring similar expenditure or investment. Therefore, it is argued that manufacturers of original drugs should be encouraged and rewarded. Under this argument, data exclusivity represents legislative protection for the complex, time consuming and expensive R&D exercises which original manufacturers undertake. The protection exists for a limited time, before competitors are permitted to use this data to obtain approval of generic alternatives.

Counter to this, many generic drug manufacturers and public interest groups maintain a stance against data exclusivity. Their primary argument is that data exclusivity, even for a finite time period, negatively impacts access and affordability of life saving drugs, particularly in the third world and developing economies. They state that rigidly protecting the rights of the original drug producer, effectively excluding generic drug producers from the market, could cause an unbalanced market structure to develop. In practice, generic drug manufacturers generally have less financial capability to conduct these expensive and time consuming tests. Even if generic drug manufacturers have the financial capacity to conduct such tests, doing so will inevitably increase the downstream prices of the generic drugs. Ethical questions inevitably arise during clinical processes due to their frequent involvement of animals and volunteer patients as test subjects to determine a product's efficacy, quality and biosafety. Generic drug producers argue that it is wasteful and unethical to repeat clinical trials simply in order to gain the MoH's marketing approval.

B. Duration Of Data Exclusivity

When the data exclusivity period expires, generic drug producers are allowed to enter the market. Therefore, the duration of the exclusivity period is of key importance to all parties involved. The data exclusivity period varies from country to country, ranging from five to ten years.

As an example, European Union legislation grants a data exclusivity period which lasts eight years, plus an additional two years (and may be extended for another year). Turkish legislation has not established a data exclusivity period akin to the period regulated under the European Union legislation. According to Article 9/a(3) of the Regulation, original pharmaceutical products which have been licensed in a Customs Union Member State are subject to a data exclusivity period of six years. This term of six years starts from the "first" licensing of such original product in any of the Customs Union Member State. If a Turkish patent exists, the data exclusivity will end when the patent expires, even if this is earlier than six years.

Basically, the period of data exclusivity depends on the term of any Turkish patent which covers the active substance of the biological reference product. Therefore, to determine the data exclusivity period in Turkey, it is important to know whether patent protection exists or not. For example, a pharmaceutical product (A) receives a marketing authorization in a country which is a member of the European Union–Turkey Customs Union in September 2013 and this is the first authorization date in any of the member States to the Customs Union. Accordingly, the data exclusivity will start from September 2013 and remain for six years. However, if there is a Turkish patent covering (A) which expires in August 2014, then the data exclusivity for (A) would only exist until August 2014, when the Turkish patent expires.

C. Patent Protection For Pharmaceutical Drug Products – A Different Type Of Protection To Data Exclusivity

A pharmaceutical drug product can hold both data exclusivity and patent protection, but each provides a different type of protection. The main purpose of data exclusivity is maintaining confidentiality of data and enabling the original drug producers to keep competitors away from its market share. Patent protection allows the right holders to enjoy the exclusive use of theirpatented information and enables the right holders to prevent other parties from selling, importing and exporting the patented products. Data exclusivity is especially vital where no patent protection exists for a pharmaceutical drug product.

For products protected by a patent in the European Union, it is possible to extend the monopoly period of a product beyond the expiry of the patent registration. The practice is called the Supplementary Protection Certificate for Medicinal Products (SPC) and was introduced on 2 January 1993 by 1768/92 EEC Directive. In Turkey, patent protection rights terminate completely on the expiry of the patent protection term. Turkish law does not contain a mechanism to extend the protection period, similar to the supplementary protection certificate system which exists in the European Union. As a result, Turkish drug producers may only benefit from patent protection for the period defined by the patent term.

Some companies prefer to protect their innovative work by closely maintaining its confidentiality, rather than register the drug product as a patent where the whole invention is publically disclosed. The downside of this approach is that if another party independently develops the same information, data, process etc., then there would be no violation of the earlier party's legal rights to that information. If the earlier party holds a registered patent, the later party would be in violation of this intellectual property right.

D. Patent Protection Laws Are Insufficient On Their Own To Establish A Data Exclusivity Framework In Turkey

Patent protection generally and mainly is harmonized at international level by the Paris Convention (1967) on the protection of Industrial Property and then Trade-Related Aspects of Intellectual Property Rights - TRIPS agreement ("TRIPS") annexed to Agreement Establishing the World Trade Organization. The Grand National Assembly of Turkey ratified the main agreement and its annex TRIPS in January 26, 1995. In order to come into compliance with these agreements, Turkey has taken steps in the Intellectual Property arena.

Turkish law contained no patent protection for pharmaceuticals until 1995, when the Decree Law No. 551 concerning the Protection of Patent Rights was enacted. Article 83/3 of the Patent Decree Law provides protection for undisclosed information, but does not state a specific time period for exclusivity:

"Where an application for patent has been filed for pharmaceutical or veterinary products/drugs and for chemicals destined to agriculture, the authorities issuing authorizations/licenses for the manufacture and sale of such products and requesting for this purpose information and test results, that were not disclosed to the public and the realization and accumulation of which requires considerable expenses and efforts, shall keep such information and test results secret/confidential. The authority asking for such information and test results shall take the necessary measures to prevent unjustified/illegitimate use thereof".


Article 83/3 of the Patent Decree Law is analogous to Article 39/3 of the international TRIPS Agreement. However, since Article 83/3 of the Patent Decree Law does not state a time period, on its own, this Article is arguably insufficient to explicitly establish a data exclusivity framework in Turkey. Despite this, pharmaceutical companies were using the TRIPS Agreement and local Patent Decree Law as the basis of their arguments in favor of data exclusivity periods existing in Turkey.

E. The Regulation On Licensing Of Human Medicinal Products Clearly Established A Data Exclusivity Framework In 2005

The situation in Turkey was clarified in 2005 when the Regulation on Licensing of Human Medicinal Products was introduced, ten years after the Patent Decree Law. Article 9 of the Regulation clearly provides data exclusivity protection for a specific six year period. Thus, a data exclusivity framework was explicitly introduced to Turkish legislation.

The Regulation introduces the data exclusivity framework during its discussion of the "Abbreviated Application" procedure. This procedure allows generic drug producers to obtain a marketing authorization without having to submit the results of toxicological and pharmacological tests or clinical trials in certain circumstances.

According to Article 9/a of the Regulation, applicants can obtain a marketing authorization from the MoH without submitting pre-clinical tests or clinical trials if:

  1. The product is similar in principle to a pharmaceutical product which has previously been authorized in Turkey and the marketing authorization holder of the original product gives its consent for the applicant to use this information for the purpose of obtaining a marketing authorization (Article 9/a(1) of the Regulation), or
  2. The components of the pharmaceutical product have reasonable activity and admissible reliability settled in medical utilization (Article 9/a(2) of the Regulation), or
  3. The data exclusivity period for the original pharmaceutical product, which is similar in principle to the generic product, has expired (Article 9/a(3) of the Regulation).

Nevertheless, for any product that provides different therapeutic indications, usage and doses from a product that has already been launched to market, it is necessary to submit clinical trial results and other toxicological and pharmacologic trial results.

In practice, without having any legal grounds, the MoH allows abbreviated marketing authorization applications to be made within the data exclusivity protection period, but withholds the marketing authorization until the original product's data exclusivity period expires. If the MoH only accepted marketing authorization applications after the six year marketing authorization period expired, no generic product would be launched to market until the end of MoH's evaluation of the abbreviated marketing authorization applications. If the MoH took this approach, it would in effect allow an extension of the data exclusivity protection period, beyond the six years stated in the Regulation. Accordingly, by accepting abbreviated marketing authorization applications within the data exclusivity protection period, the MoH shows that it does not intend the original product to benefit from data exclusivity for more than the strict six year period.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Authors
Similar Articles
Relevancy Powered by MondaqAI
 
Some comments from our readers…
“The articles are extremely timely and highly applicable”
“I often find critical information not available elsewhere”
“As in-house counsel, Mondaq’s service is of great value”

Related Topics
 
Similar Articles
Relevancy Powered by MondaqAI
Related Articles
 
Up-coming Events Search
Tools
Print
Font Size:
Translation
Channels
Mondaq on Twitter
 
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
 
Email Address
Company Name
Password
Confirm Password
Position
Mondaq Topics -- Select your Interests
 Accounting
 Anti-trust
 Commercial
 Compliance
 Consumer
 Criminal
 Employment
 Energy
 Environment
 Family
 Finance
 Government
 Healthcare
 Immigration
 Insolvency
 Insurance
 International
 IP
 Law Performance
 Law Practice
 Litigation
 Media & IT
 Privacy
 Real Estate
 Strategy
 Tax
 Technology
 Transport
 Wealth Mgt
Regions
Africa
Asia
Asia Pacific
Australasia
Canada
Caribbean
Europe
European Union
Latin America
Middle East
U.K.
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.

Disclaimer

The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.

General

Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions